{"id":"W7116681136","doi":"10.1158/1078-0432.ccr-25-1197","title":"INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Foundation Medicine; MacroGenics; BeiGene; Astellas Pharma; Mylan; Regeneron Pharmaceuticals; Gilead Sciences; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Head and neck squamous-cell carcinoma; Head and neck; Placebo; Basal cell; Phases of clinical research; Head and neck cancer; Carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001931122,0.001411487,0.001984567,0.0003948537,0.0005086198,0.0008161833,0.0009737646,0.001324645,0.00448552],"category_scores_gemma":[0.001046135,0.0006070455,0.001504556,0.0003278611,0.00104298,0.000834765,0.0003992211,0.002992411,0.0008565358],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001070939,"about_ca_system_score_gemma":0.002465029,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008626119,"about_ca_topic_score_gemma":0.003197411,"domain_scores_codex":[0.9995413,0.0002220785,0.00002443662,0.00006843883,0.00004692186,0.00009687422],"domain_scores_gemma":[0.999306,0.0001184679,0.0001379821,0.00007283199,0.0000440543,0.0003207371],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8858745,0.05629404,0.003063366,0.0007108715,0.000878068,0.0001310333,0.0001514994,0.0009674567,0.01607777,0.0001666082,0.001924064,0.03376081],"study_design_scores_gemma":[0.8639921,0.1305049,0.002837487,0.00001595845,0.0002321086,0.00007048066,0.00001678777,0.0004649768,0.001095951,0.00007532308,0.0006800331,0.00001375857],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890217,0.001269652,0.0004894421,0.0004112084,0.000195359,0.006388752,0.000776404,0.0001167866,0.001330643],"genre_scores_gemma":[0.985568,0.0009131305,0.002223816,0.001130907,0.000227742,0.006568999,0.001237085,0.00003400371,0.002096338],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00448552,"threshold_uncertainty_score":0.01500553,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1095027964643848,"score_gpt":0.4662303413668743,"score_spread":0.3567275449024895,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}